Zenith Drugs (NSE:ZENITHDRUG) Stock Based Compensation: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
35 GF Score
Price ₹47.80
! 8 Warning Signs
View Full Analysis

What is Zenith Drugs Stock Based Compensation?

Zenith Drugs NSE:ZENITHDRUG +4.03% 35 Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 35/100. The stock has 8 warning signs investors should review.

Zenith Drugs's Stock Based Compensation for the six months ended in Mar. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Zenith Drugs Stock Based Compensation Related Terms

Zenith Drugs Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Stock Based Compensation Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ZENITHDRUG
35GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Stock Based Compensation of ₹0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zenith Drugs and its competitors.
Is Zenith Drugs' Stock Based Compensation too high?
Zenith Drugs' current Stock Based Compensation is ₹0 Mil. Overall, Zenith Drugs has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Stock Based Compensation compare to ZTS?
Zenith Drugs' Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zenith Drugs and its competitors. Zenith Drugs's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Stock Based Compensation of ₹0 Mil. The current Stock Based Compensation is ₹0 Mil. Zenith Drugs' overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
35GF Score

Get the complete analysis for NSE:ZENITHDRUG

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹47.80
Price